TY - JOUR
T1 - Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
AU - Safra, Tamar
AU - Menczer, Joseph
AU - Bernstein, Rinat
AU - Shpigel, Shulem
AU - Inbar, Moshe J.
AU - Grisaru, Dan
AU - Golan, Abraham
AU - Levy, Tally
PY - 2007/4
Y1 - 2007/4
N2 - Objectives.: We assessed the efficacy and toxicity of once-weekly topotecan (Hycamtin®; GlaxoSmithKline) for relapsed or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC). Methods.: Patients with recurrent or persistent EOC and PPC previously treated with ≥ 1 course of platinum-based chemotherapy were treated with weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle in this prospective open-label, single-arm, phase II study. Results.: The median age of the 63 study patients was 63 years (range, 36-88); patients had been previously exposed to a median of 1 course (range, 1-4) of chemotherapy. A median of 5 courses (range, 1-16) were administered. Median follow-up time was 13. 2 month s (range, 1.5-39.0). The overall response rate (RR) was 23.8%, of which 17.5% (11 patients) represented a complete response and 6.3% (4 patients) a partial response. Patients with platinum-sensitive disease had a RR of 20%, whereas patients with platinum-resistant disease had a RR of 28.6%. Median time to progression was 6.2 months (95% confidence interval: 4.43, 7.97), and median survival from initiation of topotecan therapy was 22.3 months (95% confidence interval: 14.56, 30.04). Hematologic toxicities included grade 3 anemia in 3 (4.8%) patients, grade 3 thrombocytopenia in 3 (4.8%) patients, and grades 3-4 neutropenia in 5 (7.9%) patients. Dose reductions, granulocyte colony-stimulating factor, and erythropoietin support were required by 10 (15.9%), 6 (9.5%), and 16 (25.4%) patients, respectively. The most frequent nonhematologic toxicities were grades 2-3 fatigue in 10 (15.9%) patients and grades 2-3 nausea/vomiting in 3 (4.7%) patients. Conclusion.: Weekly administration of topotecan 4.0 mg/m2 is active and well tolerated by patients with recurrent or persistent EOC and PPC.
AB - Objectives.: We assessed the efficacy and toxicity of once-weekly topotecan (Hycamtin®; GlaxoSmithKline) for relapsed or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC). Methods.: Patients with recurrent or persistent EOC and PPC previously treated with ≥ 1 course of platinum-based chemotherapy were treated with weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle in this prospective open-label, single-arm, phase II study. Results.: The median age of the 63 study patients was 63 years (range, 36-88); patients had been previously exposed to a median of 1 course (range, 1-4) of chemotherapy. A median of 5 courses (range, 1-16) were administered. Median follow-up time was 13. 2 month s (range, 1.5-39.0). The overall response rate (RR) was 23.8%, of which 17.5% (11 patients) represented a complete response and 6.3% (4 patients) a partial response. Patients with platinum-sensitive disease had a RR of 20%, whereas patients with platinum-resistant disease had a RR of 28.6%. Median time to progression was 6.2 months (95% confidence interval: 4.43, 7.97), and median survival from initiation of topotecan therapy was 22.3 months (95% confidence interval: 14.56, 30.04). Hematologic toxicities included grade 3 anemia in 3 (4.8%) patients, grade 3 thrombocytopenia in 3 (4.8%) patients, and grades 3-4 neutropenia in 5 (7.9%) patients. Dose reductions, granulocyte colony-stimulating factor, and erythropoietin support were required by 10 (15.9%), 6 (9.5%), and 16 (25.4%) patients, respectively. The most frequent nonhematologic toxicities were grades 2-3 fatigue in 10 (15.9%) patients and grades 2-3 nausea/vomiting in 3 (4.7%) patients. Conclusion.: Weekly administration of topotecan 4.0 mg/m2 is active and well tolerated by patients with recurrent or persistent EOC and PPC.
KW - Chemotherapy
KW - Primary peritoneal
KW - Recurrent epithelial ovarian
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=33947325163&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2006.11.017
DO - 10.1016/j.ygyno.2006.11.017
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:33947325163
SN - 0090-8258
VL - 105
SP - 205
EP - 210
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -